Objective: To evaluate the efficacy of imidafenacin on nocturia and sleep disorder in patients with overactive bladder (OAB).
Patients and Methods: A prospective multicenter study of imidafenacin 0.1 mg twice daily for patients with OAB and nocturia was conducted. At baseline and at week 4 and 8, patients were assessed using the overactive bladder symptom score (OABSS), frequency volume charts (FVC) and the Pittsburgh Sleep Quality Index (PSQI).
Results: Treatment with imidafenacin significantly improved OAB symptoms. Imidafenacin also improved PSQI, especially subjective sleep quality, sleep latency and daytime dysfunction. In FVC, the number of daytime voids and nighttime voids significantly decreased and average voided volume significantly increased after imidafenacin. Subanalysis of FVC based on the patients' age revealed that nocturnal polyuria was more often found in patients aged 75 years or over than in those aged under 75 years (79 vs. 55%, p < 0.05). Treatment with imidafenacin significantly reduced the nocturnal polyuria index only in patients aged 75 years or over.
Conclusions: Imidafenacin can improve nocturia and sleep disorder in patients with OAB. The efficacy of imidafenacin on nocturia is attributable to an increase in bladder capacity and a decrease in nocturnal urine volume. We conclude that imidafenacin is an effective and safe drug for nocturia in patients with OAB.
Written by:
Wada N, Watanabe M, Kita M, Matsumoto S, Osanai H, Yamaguchi S, Numata A, Fujisawa M, Saga Y, Hou K, Iuchi H, Niibori D, Kura T, Taniguchi A, Kunieda M, Nakata Y, Kakizaki H. Are you the author?
Department of Renal and Urologic Surgery, Asahikawa Medical University, Asahikawa, Japan.
Reference: Urol Int. 2012 Jul 25. Epub ahead of print.
doi: 10.1159/000339750
PubMed Abstract
PMID: 22832092